- Home
- FGNX vs KALA Comparison
FGNX vs KALA Comparison
Compare FGNX & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGNX
- KALA
- Stock Information
- Founded
- FGNX 1932
- KALA 2009
- Country
- FGNX United States
- KALA United States
- Employees
- FGNX N/A
- KALA N/A
- Industry
- FGNX Property-Casualty Insurers
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- FGNX Finance
- KALA Health Care
- Exchange
- FGNX Nasdaq
- KALA Nasdaq
- Market Cap
- FGNX 25.2M
- KALA 26.2M
- IPO Year
- FGNX N/A
- KALA 2017
- Fundamental
- Price
- FGNX $5.98
- KALA $2.05
- Analyst Decision
- FGNX
- KALA Strong Buy
- Analyst Count
- FGNX 0
- KALA 3
- Target Price
- FGNX N/A
- KALA $32.67
- AVG Volume (30 Days)
- FGNX 696.6K
- KALA 2.1M
- Earning Date
- FGNX 08-07-2025
- KALA 11-11-2025
- Dividend Yield
- FGNX N/A
- KALA N/A
- EPS Growth
- FGNX N/A
- KALA N/A
- EPS
- FGNX 2.41
- KALA N/A
- Revenue
- FGNX $24,184,000.00
- KALA N/A
- Revenue This Year
- FGNX N/A
- KALA N/A
- Revenue Next Year
- FGNX N/A
- KALA N/A
- P/E Ratio
- FGNX $69.79
- KALA N/A
- Revenue Growth
- FGNX 24.03
- KALA N/A
- 52 Week Low
- FGNX $5.75
- KALA $1.10
- 52 Week High
- FGNX $41.25
- KALA $20.60
- Technical
- Relative Strength Index (RSI)
- FGNX N/A
- KALA 27.66
- Support Level
- FGNX N/A
- KALA $16.36
- Resistance Level
- FGNX N/A
- KALA $19.77
- Average True Range (ATR)
- FGNX 0.00
- KALA 2.00
- MACD
- FGNX 0.00
- KALA -1.22
- Stochastic Oscillator
- FGNX 0.00
- KALA 4.85
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.